Table 2 Reasons for undergoing CIRTin CIRTgroup and CIRT details and results
Reasons for CIRT | Tumor size (mm) | C/T ratio | CIRT dose Gy(RBE) | Complication(> 2) | Follow-up (Months) | Outcomes | |
|---|---|---|---|---|---|---|---|
CIRT#1 | LPH and PL | 18 | 0.11 | 32 | 29 | DC | |
CIRT#2 | LHF | 19 | 0.47 | 36 | – | 35 | DO (AMI) |
CIRT#3 | LPF | 44 | 0.50 | 38 | – | 67 | DO (TR) |
CIRT#4 | CJ | 28 | 0.089 | 40 | – | 70 | DO (TAA) |
CIRT#5 | LPH and PL | 22 | 0.27 | 42 | – | 180 | AR |
CIRT#6 | RS | 32 | 0.13 | 44 | – | 94 | DO (MOF) |
CIRT#7 | RS | 18 | 0.22 | 40 | – | 148 | DO (RF) |
CIRT#8 | RS | 21 | 0.00 | 44 | – | 148 | AR |
CIRT#9 | RS | 43 | 0.15 | 46 | – | 110 | DO (Pneumonia) |
CIRT#10 | RS | 20 | 0.050 | 46 | – | 66 | DO (lleus) |
CIRT#11 | RS | 22 | 0.023 | 46 | – | 150 | AR |
CIRT#12 | RS | 25 | 0.080 | 46 | – | 140 | AR |
CIRT#13 | RS | 22 | 0.30 | 48 | – | 130 | DO (Senility) |
CIRT#14 | RS | 16 | 0.00 | 48 | – | 110 | DO (Senility) |